The Food and Drug Administration is expected to decide by Friday whether to grant accelerated approval for Eisai and Biogen’s experimental Alzheimer’s drug, lecanemab.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.